Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ABLS licenses IP from Harvard

22 Jun 2015 07:00

RNS Number : 7791Q
Allied Minds PLC
22 June 2015
 



 

Media Contact:

Christine Dunn

ArcPoint Strategic Communications

cdunn@arcpointstrategy.com

617.484.1660 x101

 

 

Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University

 

· Allied-Bristol Life Sciences (ABLS) has licensed intellectual property developed in Professor Malcolm Whitman's laboratory at Harvard.

· The intellectual property includes lead molecules and a differentiated mechanism to develop drugs for treating chronic fibrotic and autoimmune diseases.

 

Boston (June 22, 2015) - Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned by Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), today announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Whitman's lab at the Harvard School of Dental Medicine.

 

Malcolm Whitman, PhD, Professor of Developmental Biology, and Tracy Keller, PhD, an instructor in the Department of Developmental Biology, have identified the mechanism of action behind a known natural product, halofuginone (HF). HF is a chemical compound based on an active ingredient in the root of the blue evergreen hydrangea (Dichroa febrifuga), which has been used in traditional Chinese medicine for centuries.

 

Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Children's Hospital, Professor Whitman's lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction (AAR) response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases.

 

 "Our research is at the right stage for an infusion of resources and expertise to accelerate its progression," said Dr. Whitman. "We look forward to seeing the development of lead compounds from our laboratories into novel therapeutics for the treatment of fibrotic disease, and potentially other indications."

 

"The work done by Whitman and Keller is a terrific example of a promising early-stage therapeutic application that has the potential to make a significant difference to patients," said Satish Jindal, Chief Executive Officer of ABLS. "We are pleased to support this project through the next phase of drug discovery to identify a candidate for clinical development. This is a great example of the type of university research that ABLS looks for, where our expertise and experience can accelerate bringing new therapies to patients that need them."

 

The licensing agreement with Harvard's Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitman's lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.

 

For more information about Allied-Bristol Life Sciences, please visit www.ablifescience.com.

 

About Allied-Bristol Life SciencesAllied-Bristol Life Sciences (ABLS) is a jointly owned enterprise between Allied Minds and Bristol-Myers Squibb Co. Based upon compelling biological discoveries and insights from scientists at leading U.S. research institutions, ABLS identifies, sources and de-risks promising, early-stage therapeutic opportunities, from discovery through pre-clinical development, in key therapeutic areas, including fibrosis, cardiovascular diseases, oncology, immunology, virology and genetically defined diseases. For more information, visit www.ablifescience.com.

 

About Harvard University's Office of Technology Development

Harvard's Office of Technology Development (OTD) is responsible for all activities pertaining to the evaluation, patenting and licensing of new inventions and discoveries made at Harvard University and Harvard Medical School. Harvard OTD also serves to further the development of Harvard technologies through the establishment of sponsored research collaborations with industry. The mission of Harvard OTD is to promote the public good by fostering innovation and translating new inventions made at Harvard into useful products that are available and beneficial to society. For more information, please visit http://otd.harvard.edu.

 

About Allied MindsAllied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com. 

 

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.

Allied Minds Forward-Looking StatementThis press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the licensing agreement mentioned in this release will lead to identifying a pre-clinical candidate. Nor is there any guarantee that if one is identified, it will be successfully developed for or approved for any of the indications described in this release. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2014 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUASRRVAANUUR
Date   Source Headline
13th Nov 20174:42 pmRNSBlocklisting Six Monthly Return
13th Nov 20174:24 pmRNSBlocklisting Six Monthly Return
31st Oct 20174:47 pmRNSTotal Voting Rights
30th Oct 20177:00 amRNSAllied-Bristol Life Sciences forms ABLS IV
25th Oct 20177:00 amRNSAllied Minds Capital Markets Day: 18 January 2018
16th Oct 20177:59 amRNSAllied Minds: STT and TEL to jointly develop MRAM
6th Oct 20174:42 pmRNSTotal Voting Rights
5th Oct 20177:00 amRNSSTT announces $22.8m convertible bridge facility
28th Sep 20177:00 amRNSSciFluor SF0166 study positive top-line results
19th Sep 20177:00 amRNSDirectorate Change
14th Sep 20177:00 amRNSFederated Wireless $42m fundraise & product launch
13th Sep 20174:40 pmRNSSecond Price Monitoring Extn
13th Sep 20174:35 pmRNSPrice Monitoring Extension
1st Sep 201711:43 amRNSTotal Voting Rights
17th Aug 20177:00 amRNSHalf-year Report
8th Aug 20175:36 pmRNSHolding(s) in Company
2nd Aug 20177:00 amRNSNotice of Results
26th Jul 20177:00 amRNSALM subsid Signature Medical $2.5 million Series A
12th Jul 20177:00 amRNSBridgeSat, Inc. appoints Barry Matsumori as CEO
11th Jul 20174:35 pmRNSSpin Transfer Tech's appoints Tom Sparkman CEO
30th Jun 20175:29 pmRNSTotal Voting Rights
29th Jun 20177:00 amRNSAppointment of Head of Technology Investments
13th Jun 20177:05 amRNSDirector/PDMR Shareholding
13th Jun 20177:05 amRNSDirector/PDMR Shareholding
13th Jun 20177:00 amRNSDirector/PDMR Shareholding
13th Jun 20177:00 amRNSDirector/PDMR Shareholding
13th Jun 20177:00 amRNSDirector/PDMR Shareholding
13th Jun 20177:00 amRNSDirector/PDMR Shareholding
8th Jun 20177:00 amRNSDirector/PDMR Shareholding
8th Jun 20177:00 amRNSDirector/PDMR Shareholding
1st Jun 20175:02 pmRNSResult of AGM
30th May 20177:00 amRNSJill Smith Appointed As CEO and President
19th May 20174:58 pmRNSBlock Listing Six Monthly Return
12th May 20172:13 pmRNSBlock Listing of Shares
5th May 20177:00 amRNSBridgeSat raises $6 million in Series A financing
28th Apr 20173:14 pmRNSNotice of AGM; Annual Report
27th Apr 20177:00 amRNSAnnual Financial Report
20th Apr 20174:28 pmRNSHolding(s) in Company
18th Apr 20175:12 pmRNSHolding(s) in Company
7th Apr 20179:41 amRNSHolding(s) in Company
6th Apr 20175:24 pmRNSHolding(s) in Company
5th Apr 20174:35 pmRNSPrice Monitoring Extension
5th Apr 20177:00 amRNSReallocation of capital and resources
31st Mar 20173:56 pmRNSTotal Voting Rights
16th Mar 20175:27 pmRNSHolding(s) in Company
13th Mar 20177:00 amRNSJill Smith appointed interim CEO of Allied Minds
1st Mar 20174:45 pmRNSTotal Voting Rights
15th Feb 20172:57 pmRNSHolding(s) in Company
14th Feb 20174:23 pmRNSTotal Voting Rights
7th Feb 20177:00 amRNSHawkEye 360 Completes Second Closing of Series A

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.